ImmunityBio, Inc. (NASDAQ:IBRX) Shares Acquired by Mirae Asset Global Investments Co. Ltd.

Mirae Asset Global Investments Co. Ltd. boosted its holdings in ImmunityBio, Inc. (NASDAQ:IBRX) by 22.0% in the third quarter, HoldingsChannel reports. The firm owned 25,192 shares of the company’s stock after purchasing an additional 4,545 shares during the period. Mirae Asset Global Investments Co. Ltd.’s holdings in ImmunityBio were worth $99,000 as of its most recent SEC filing.

A number of other hedge funds have also made changes to their positions in IBRX. Bleakley Financial Group LLC acquired a new stake in shares of ImmunityBio during the 1st quarter valued at approximately $58,000. Lazard Asset Management LLC boosted its stake in ImmunityBio by 102.6% during the 1st quarter. Lazard Asset Management LLC now owns 13,019 shares of the company’s stock valued at $68,000 after purchasing an additional 6,593 shares during the period. Algert Global LLC acquired a new stake in shares of ImmunityBio in the second quarter valued at approximately $86,000. Axxcess Wealth Management LLC bought a new stake in shares of ImmunityBio during the first quarter valued at approximately $85,000. Finally, Simplicity Wealth LLC boosted its position in shares of ImmunityBio by 46.0% during the second quarter. Simplicity Wealth LLC now owns 15,806 shares of the company’s stock worth $100,000 after buying an additional 4,983 shares during the period. Institutional investors and hedge funds own 8.58% of the company’s stock.

Analyst Upgrades and Downgrades

IBRX has been the topic of several recent analyst reports. EF Hutton Acquisition Co. I raised ImmunityBio to a “strong-buy” rating in a research note on Wednesday, October 23rd. Piper Sandler reduced their price objective on shares of ImmunityBio from $6.00 to $4.75 and set a “neutral” rating for the company in a report on Monday, August 19th.

ImmunityBio Price Performance

Shares of NASDAQ:IBRX opened at $5.20 on Tuesday. The stock has a market cap of $3.62 billion, a price-to-earnings ratio of -5.36 and a beta of 0.98. ImmunityBio, Inc. has a 12 month low of $2.66 and a 12 month high of $10.53. The stock’s 50 day moving average price is $3.88 and its 200 day moving average price is $5.35.

ImmunityBio (NASDAQ:IBRX) last announced its quarterly earnings data on Monday, August 12th. The company reported ($0.20) earnings per share for the quarter, missing the consensus estimate of ($0.17) by ($0.03). The firm had revenue of $1.05 million during the quarter, compared to analyst estimates of $2.53 million. On average, sell-side analysts expect that ImmunityBio, Inc. will post -0.86 EPS for the current year.

About ImmunityBio

ImmunityBio, Inc, a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies.